Illumina Ventures — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investors5AM VenturesOUP (Osage University Partners)AlexandriaLilly Asia VenturesS28 CapitalUPMC Enterprises
Integrated Biosciences is a biotech company developing small molecule therapeutics for age-related diseases, using optogenetics, chemistry, and AI to study aging biology.
AI & Machine LearningBiotechLongevityRedwood City, US
Felix Wong(Executive Officer, Director)inDaniel J. Anderson(Chief Scientific Officer)inThemasap Khan(Director)
BoardKeith Loebner(Director)
Co-investorsSutter Hill VenturesCivilization Ventures Management, LlcOverlap Holdings
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalLongwall Venture Partners LLPM VenturesOMX VenturesARCH Venture Partners
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesMedical Excellence CapitalVivo Capital+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




















